CTNNB1 and metastatic malignant neoplasm in the lymph nodes: During the disease course, 66% (n = 25) of patients with a CTNNB1 mutation developed lymph node metastasis, 32% (n = 12) lung metastasis, 29% (n = 11) hepatic metastasis, 29% (n = 11) metastasis within the central nervous system (CNS), and 11% (n = 4) bone metastasis.